Cash flow Arrowhead Pharmaceuticals, Inc.

Equities

ARWR

US04280A1007

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 20/09/2024 BST			5-day change	1st Jan Change
20.80 ^USD	-1.61%		+2.79%	-32.03%

09-10	Arrowhead Pharmaceuticals' Plozasiran Receives FDA Breakthrough Therapy Designation	MT
09-10	Arrowhead Pharmaceuticals Gets FDA Breakthrough Designation for Plozasiran	DJ

2fc3981c90e3fa51a6987d6a7e6c5.fMZfRxJrawoha3e7-NdZkRU1fR7ZucZdk0QvIdIUkkk.Bb9qH1MFCW9nBB3UwbRq8lZvFF2X7usv3j5iTuZ4xiMJkD4wQBJfRGcoGA

Published financial data: ARROWHEAD PHARMACEUTICALS, INC.

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: September	2019	2020	2021	2022	2023
Revenues	169M	87.99M	138M	243M	241M
Total Revenues	169M	87.99M	138M	243M	241M
Gross Profit	169M	87.99M	138M	243M	241M
Selling General & Admin Expenses, Total	26.56M	56.41M	88.68M	137M	109M
Stock-Based Compensation (IS)	-	-	-	-	-
R&D Expenses	81.05M	125M	199M	284M	337M
Depreciation & Amortization - (IS)	-	-	-	-	-
Other Operating Expenses, Total	108M	181M	287M	422M	446M
Operating Income	61.19M	-93.16M	-149M	-179M	-205M
Interest Expense, Total	-42.23K	-	-	-	-18.33M
Interest And Investment Income	7M	9.19M	6.12M	5.03M	15.3M
Net Interest Expenses	6.96M	9.19M	6.12M	5.03M	-3.03M
Income (Loss) On Equity Invest.	-	-	-	-	-
Other Non Operating Income (Expenses)	-	-583K	2.07M	5.2M	1.54M
EBT, Excl. Unusual Items	68.15M	-84.55M	-141M	-168M	-206M
Gain (Loss) On Sale Of Investments	-	-	-	-4.43M	-
Gain (Loss) On Sale Of Assets	-	-	-	-	-
Asset Writedown	-	-	-	-	-
In Process R&D Expenses	-	-	-	-	-
Insurance Settlements	-	-	-	-	-
Other Unusual Items	-	-	-	-	-
EBT, Incl. Unusual Items	68.15M	-84.55M	-141M	-173M	-206M
Income Tax Expense	174K	2.4K	2K	3.78M	2.78M
Earnings From Continuing Operations	67.97M	-84.55M	-141M	-176M	-209M
Net Income to Company	67.97M	-84.55M	-141M	-176M	-209M
Minority Interest	-	-	-	431K	4M
Net Income - (IS)	67.97M	-84.55M	-141M	-176M	-205M
Net Income to Common Incl Extra Items	67.97M	-84.55M	-141M	-176M	-205M
Net Income to Common Excl. Extra Items	67.97M	-84.55M	-141M	-176M	-205M
Per Share Items
Net EPS - Basic	0.72	-0.84	-1.36	-1.67	-1.92
Basic EPS - Continuing Operations	0.72	-0.84	-1.36	-1.67	-1.92
Basic Weighted Average Shares Outstanding	93.86M	101M	104M	105M	107M
Net EPS - Diluted	0.69	-0.84	-1.36	-1.67	-1.92
Diluted EPS - Continuing Operations	0.69	-0.84	-1.36	-1.67	-1.92
Diluted Weighted Average Shares Outstanding	98.61M	101M	104M	105M	107M
Normalized Basic EPS	0.45	-0.52	-0.85	-0.99	-1.17
Normalized Diluted EPS	0.43	-0.52	-0.85	-0.99	-1.17
American Depositary Receipts Ratio (ADR)	0.12	0.12	0.12	0.12	0.12
Supplemental Items
EBITDA	65.63M	-87.22M	-141M	-168M	-193M
EBITA	62.89M	-91.46M	-147M	-177M	-203M
EBIT	61.19M	-93.16M	-149M	-179M	-205M
EBITDAR	67.28M	-80.88M	-131M	-152M	-173M
Effective Tax Rate - (Ratio)	0.25	-0	-0	-2.19	-1.35
Current Domestic Taxes	174K	2.4K	2K	304K	2.78M
Current Foreign Taxes	-	-	-	3.48M	-
Total Current Taxes	174K	2.4K	2K	3.78M	2.78M
Normalized Net Income	42.59M	-52.84M	-88.03M	-105M	-125M
Supplemental Operating Expense Items
General and Administrative Expenses	26.56M	52.28M	78.64M	122M	89.13M
Research And Development Expense From Footnotes	81.05M	129M	206M	297M	353M
Net Rental Expense, Total	1.65M	6.34M	10.04M	15.86M	19.68M
Imputed Operating Lease Interest Expense	-	-	-	-	12.41M
Imputed Operating Lease Depreciation	-	-	-	-	7.27M
Stock-Based Comp., R&D Exp. (Total)	3.52M	16.28M	25.74M	32.37M	34.33M
Stock-Based Comp., G&A Exp. (Total)	8.88M	27.11M	50.93M	88.52M	43.8M
Stock-Based Comp., Other (Total)	323	-	-	1K	-
Total Stock-Based Compensation	12.39M	43.38M	76.67M	121M	78.13M

Fiscal Period: September	2019	2020	2021	2022	2023
Assets
Cash And Equivalents	222M	144M	184M	108M	103M
Short Term Investments	36.9M	172M	183M	268M	293M
Total Cash And Short Term Investments	259M	315M	368M	376M	396M
Accounts Receivable, Total	661K	846K	10.26M	1.41M	-
Total Receivables	661K	846K	10.26M	1.41M	-
Prepaid Expenses	3.32M	4.25M	4.36M	7.29M	8.81M
Restricted Cash	-	-	-	-	7.9M
Other Current Assets, Total	2.56M	1.78M	2.19M	20.2M	7.08M
Total Current Assets	265M	322M	385M	405M	420M
Gross Property Plant And Equipment	35.3M	63.32M	88.88M	200M	378M
Accumulated Depreciation	-12.08M	-16.3M	-22.86M	-31.55M	-41.95M
Net Property Plant And Equipment	23.21M	47.02M	66.02M	169M	336M
Long-term Investments	44.18M	137M	246M	106M	-
Other Intangibles, Total	17.06M	15.36M	13.66M	11.96M	10.26M
Other Long-Term Assets, Total	144K	265K	272K	218K	210K
Total Assets	350M	523M	710M	692M	766M
Liabilities
Accounts Payable, Total	7.65M	6.83M	9.46M	2.87M	35.87M
Accrued Expenses, Total	11.46M	13.45M	20.67M	59.11M	57.73M
Current Portion of Long-Term Debt	-	-	-	-	-
Current Portion of Leases	-	1.09M	2.25M	2.78M	10.56M
Unearned Revenue Current, Total	77.77M	19.29M	114M	74.1M	866K
Other Current Liabilities	191K	17.26K	-	-	435K
Total Current Liabilities	97.07M	40.68M	147M	139M	105M
Long-Term Debt	-	-	-	-	268M
Long-Term Leases	-	20.04M	23.3M	78.8M	105M
Unearned Revenue Non Current	5.04M	-	131M	55.95M	-
Other Non Current Liabilities	3.7M	-	-	-	-
Total Liabilities	106M	60.72M	301M	274M	478M
Preferred Stock Convertible	-	-	-	-	-
Total Preferred Equity	-	-	-	-	-
Common Stock, Total	188K	195K	197K	198K	200K
Additional Paid In Capital	664M	965M	1.05B	1.22B	1.3B
Retained Earnings	-419M	-504M	-645M	-821M	-1.03B
Comprehensive Income and Other	-392K	18.43K	-69K	-136K	-3.22M
Total Common Equity	245M	462M	409M	399M	271M
Minority Interest	-555K	-	-	19.82M	15.82M
Total Equity	244M	462M	409M	418M	287M
Total Liabilities And Equity	350M	523M	710M	692M	766M
Supplemental Items
ECS Total Shares Outstanding on Filing Date	95.71M	103M	105M	106M	107M
ECS Total Common Shares Outstanding	95.51M	102M	104M	106M	107M
Book Value / Share	2.56	4.51	3.92	3.76	2.53
Tangible Book Value	228M	446M	395M	387M	261M
Tangible Book Value Per Share	2.38	4.36	3.79	3.65	2.43
Total Debt	0	21.14M	25.54M	81.58M	383M
Net Debt	-259M	-294M	-342M	-295M	-12.23M
Debt Equivalent Oper. Leases	13.24M	50.71M	80.3M	127M	157M
Minority Interest, Total (Incl. Fin. Div)	-555K	-	-	19.82M	15.82M
Account Code - Inventory Valuation	3	3	3	3	3
Land - (BS)	-	-	-	3M	3M
Machinery, Total	13.57M	21.32M	29.16M	40.46M	58.75M
Full Time Employees	134	232	329	397	525

Fiscal Period: September	2019	2020	2021	2022	2023
Net Income	67.97M	-84.55M	-141M	-176M	-205M
Depreciation & Amortization - CF	2.74M	4.24M	6.57M	8.72M	10.79M
Amortization of Goodwill and Intangible Assets - (CF)	1.7M	1.7M	1.7M	1.7M	1.7M
Depreciation & Amortization, Total	4.44M	5.94M	8.27M	10.42M	12.49M
Minority Interest in Earnings - (CF)	-	-	-	-	-
(Gain) Loss From Sale Of Asset	-	-	-	-	-
(Gain) Loss on Sale of Investments - (CF)	-	-	-	4.43M	-
Asset Writedown & Restructuring Costs	-	-	-	-	-
(Income) Loss On Equity Investments - (CF)	-	-	-	-	-
Stock-Based Compensation (CF)	12.39M	43.38M	76.67M	121M	78.13M
Other Operating Activities, Total	1.07M	525K	266K	2.48M	12.31M
Change In Accounts Receivable	-334K	-184K	-9.41M	8.84M	1.41M
Change In Accounts Payable	4.84M	-821K	2.63M	-6.59M	33M
Change in Unearned Revenues	82.8M	-63.51M	223M	-113M	-129M
Change in Other Net Operating Assets	-155K	3.83M	10.39M	11.95M	43.23M
Cash from Operations	173M	-95.39M	171M	-136M	-154M
Capital Expenditure	-12M	-11.95M	-23.57M	-52.78M	-177M
Sale of Property, Plant, and Equipment	-	-	-	-	-
Cash Acquisitions	-	-	-	-	-
Investment in Marketable and Equity Securities, Total	-35.74M	-229M	-118M	47.36M	80.58M
Other Investing Activities, Total	-	-	-	-	-
Cash from Investing	-47.75M	-241M	-142M	-5.42M	-96.16M
Long-Term Debt Repaid, Total	-2.42M	-	-	-	-
Total Debt Repaid	-2.42M	-	-	-	-
Issuance of Common Stock	68.8M	258M	11.3M	5.19M	3.05M
Repurchase of Common Stock	-	-	-	-	-
Issuance of Preferred Stock	-	-	-	-	-
Other Financing Activities, Total	-	-	-	60M	250M
Cash from Financing	66.38M	258M	11.3M	65.19M	253M
Foreign Exchange Rate Adjustments	-	-	-	-67K	-122K
Net Change in Cash	192M	-78.22M	40.85M	-76.43M	2.89M
Supplemental Items
Cash Interest Paid	27.44K	-	-	-	-
Cash Income Tax Paid (Refund)	302K	-103K	2K	2K	-
Levered Free Cash Flow	124M	-78.67M	63M	-53.34M	-254M
Unlevered Free Cash Flow	124M	-78.67M	63M	-53.34M	-243M
Change In Net Working Capital	-80.62M	57.82M	-94.77M	20.31M	28.77M
Net Debt Issued / Repaid	-2.42M	-	-	-	-

Fiscal Period: September	2019	2020	2021	2022	2023
Profitability
Return on Assets	16.58	-13.35	-15.11	-15.91	-17.58
Return on Total Capital	22.39	-16.02	-20.31	-23.88	-21.89
Return On Equity %	40.07	-23.96	-32.36	-42.67	-59.33
Return on Common Equity	39.94	-23.94	-32.36	-43.62	-61.29
Margin Analysis
Gross Profit Margin %	100	100	100	100	100
SG&A Margin	15.73	64.11	64.12	56.48	45.2
EBITDA Margin %	38.88	-99.12	-101.79	-69.11	-79.97
EBITA Margin %	37.26	-103.94	-106.54	-72.69	-84.45
EBIT Margin %	36.25	-105.87	-107.77	-73.39	-85.16
Income From Continuing Operations Margin %	40.27	-96.09	-101.85	-72.56	-86.93
Net Income Margin %	40.27	-96.09	-101.85	-72.38	-85.27
Net Avail. For Common Margin %	40.27	-96.09	-101.85	-72.38	-85.27
Normalized Net Income Margin	25.23	-60.06	-63.66	-43.06	-51.95
Levered Free Cash Flow Margin	73.27	-89.41	45.55	-21.93	-105.7
Unlevered Free Cash Flow Margin	73.28	-89.41	45.55	-21.93	-100.95
Asset Turnover
Asset Turnover	0.73	0.2	0.22	0.35	0.33
Fixed Assets Turnover	9.09	2.51	2.45	2.07	0.96
Receivables Turnover (Average Receivables)	341.44	116.78	24.91	41.7	-
Short Term Liquidity
Current Ratio	2.73	7.92	2.62	2.92	3.98
Quick Ratio	2.67	7.78	2.58	2.72	3.75
Operating Cash Flow to Current Liabilities	1.78	-2.34	1.17	-0.98	-1.46
Days Sales Outstanding (Average Receivables)	1.07	3.13	14.65	8.75	-
Long Term Solvency
Total Debt/Equity	-	4.58	6.25	19.5	133.55
Total Debt / Total Capital	-	4.38	5.88	16.32	57.18
LT Debt/Equity	-	4.34	5.7	18.84	129.87
Long-Term Debt / Total Capital	-	4.15	5.36	15.76	55.61
Total Liabilities / Total Assets	30.24	11.62	42.43	39.54	62.49
EBIT / Interest Expense	1.45K	-	-	-	-11.19
EBITDA / Interest Expense	1.55K	-	-	-	-9.43
(EBITDA - Capex) / Interest Expense	1.27K	-	-	-	-19.07
Total Debt / EBITDA	-	-0.26	-0.2	-0.54	-2.22
Net Debt / EBITDA	-3.94	3.64	2.62	1.94	0.07
Total Debt / (EBITDA - Capex)	-	-0.23	-0.17	-0.4	-1.1
Net Debt / (EBITDA - Capex)	-4.82	3.17	2.22	1.44	0.03
Growth Over Prior Year
Total Revenues, 1 Yr. Growth %	945.67	-47.87	57.16	75.89	-1.03
Gross Profit, 1 Yr. Growth %	945.67	-47.87	57.16	75.89	-1.03
EBITDA, 1 Yr. Growth %	-228.09	-232.89	61.4	19.41	14.53
EBITA, 1 Yr. Growth %	-215.96	-245.42	61.1	20	14.99
EBIT, 1 Yr. Growth %	-209.39	-252.24	59.98	19.77